InfuSystem Holdings, Inc.
AMEX:INFU · New York Stock Exchange American
+$0.09 today
Vol 0.16M · Avg 0.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
11.6%
avg 0.3%
ROIC
9.3%
avg 3.3%
ROA
6.6%
avg 0.2%
Analysis
ROE is currently the strongest return metric at 11.6% versus its period average of 0.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Carrie Lachance | President, Chief Executive Officer & Director | $998,802.00 | — | 49 | $0.00 | <0.01% |
Barry G. Steele | Executive Vice President & Chief Financial Officer | $762,199.00 | — | 55 | $121,567.00 | 0.60% |
Jerod Funke | Executive Vice President & Chief HR Officer | $617,904.00 | — | 51 | $29,654.00 | 0.15% |
Addam Chupa | Executive Vice President & Chief Information Officer | — | — | 47 | $63,154.00 | 0.31% |
Jeanie Latz | Corporate Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$150,375.24
Sells
1
$55,621.84
Net Sentiment
+$94,753.40
Net buying
Most Active
Lachance Carrie
2 transactions
Analysis
Insiders reported 5 buys worth $150,375.24 and 1 sells worth $55,621.84 over the last 12 months. That adds up to net buying of $94,753.40. Lachance Carrie was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +7.0% | +6.6% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | +64.3% | +8.5% (13yr)1 analysts |
Analysis
Recent growth has been strongest in EBIT at +64.3% over three years. Forward estimates point to EBIT at +8.5% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Electromed, Inc.
AMEX:ELMD
$307.52M
OraSure Technologies, Inc.
NASDAQ:OSUR
$287.79M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Utah Medical Products, Inc.
NASDAQ:UTMD
$216.00M
Inventiva S.A.
NASDAQ:IVA
$200.13M
KORU Medical Systems, Inc.
NASDAQ:KRMD
$183.73M
Stereotaxis, Inc.
AMEX:STXS
$179.84M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
Solana Company
NASDAQ:HSDT
$89.92M
Nyxoah S.A.
NASDAQ:NYXH
$55.05M
Who manages INFU?
InfuSystem Holdings, Inc. (INFU) lists 5 active executives. The top listed executive is Barry G. Steele, Executive Vice President & Chief Financial Officer.
Are INFU insiders buying or selling?
Recent insider activity shows net buying of $7.32M.
Explore More
Continue the stock analysis
Jump to another research area for this company.